- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00391482
Study to Reduce Intravenous Exposures (STRIVE)
Behavioral Intervention Trial to Reduce Transmission Risks and Improve HCV Treatment Access Among HCV-infected Injection Drug Users
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
The purpose of this study is to determine the efficacy of a peer-volunteer intervention to reduce high-risk transmission behaviors among hepatitis C virus (HCV)-infected young adult injection drug users (IDUs), and to identify the proportion of these individuals who would be eligible and willing to undergo treatment to eradicate HCV infection. HCV is one of the most frequently occurring human viral infections, having an estimated worldwide prevalence of 3%. In many regions of the United States, between 65% and 95% of IDUs are HCV-seropositive and capable of transmitting the infection. To date, research studies targeting infected individuals to prevent secondary transmission of chronic blood-borne viral infection have generally been limited to post-test counseling and case management. In addition, recent data suggest that medical treatment of HCV infection may be most effective when offered soon after HCV seroconversion. However, the proportion of HCV-infected IDUs who meet strict national guidelines for HCV treatment is likely to be small because treatment is usually postponed while drug use continues. Determining the proportion of infected individuals who may be both eligible and willing to undergo HCV therapy is highly important for guiding national standards and objectives to achieve greater numbers of IDUs in HCV therapy. We have previously reported that fewer than 1% of HCV-infected IDUs in Baltimore are currently receiving such therapy. Early initiation of HCV treatment among young IDUs in conjunction with a reduction in HCV transmission risk behaviors may ultimately lead to a reduction in incident HCV infection at the individual and the community levels.
This study is a randomized controlled trial to determine the efficacy of a "peer-volunteer activism" intervention to reduce distributive syringe and injection paraphernalia sharing behaviors among HCV positive IDUs and promote the uptake of HCV care and treatment. If proven effective, this intervention would substantially decrease the risk of HCV infection in the community. To address these aims, we plan to recruit, screen, and randomly assign 750 IDUs age 18-35 years who are HCV-seropositive but HIV-seronegative in Baltimore, New York and Seattle to a behavioral intervention (250 per site), and prospectively monitor participants behavior at 3- and 6-month follow-up visits.
Typ studie
Zápis
Fáze
- Fáze 2
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21205
- Johns Hopkins University, Bloomberg School of Public Health
-
-
New York
-
New York, New York, Spojené státy, 10029
- New York Academy of Medicine, Center for Urban Epidemiologic Studies
-
-
Washington
-
Seattle, Washington, Spojené státy, 98104
- Public Health Seattle & King County
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- HCV antibody positive
- age between 18 and 35 years old;
- reported injection drug use in the past 6 months
- willing to provide a blood sample for liver function testing
Exclusion Criteria:
- HIV antibody positive
- planned on moving from city within the next 12 months;
- unable to comprehend English well enough to complete English-only assessments and group sessions
Studijní plán
Jak je studie koncipována?
Detaily designu
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
---|
Self-reported frequency of distributive sharing of injection and non-injection drug equipment (i.e., lending, giving or selling used needles, syringes or paraphernalia to others)
|
Sekundární výstupní opatření
Měření výsledku |
---|
Alcohol use; disposal of syringes and paraphernalia; increased condom use; syringe exchange program use; readiness for HCV therapy and drug use cessation; and discussing HCV therapy options at a medical care visit.
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Steffanie A Strathdee, PhD, Johns Hopkins University, Bloomberg School of Public Health,
Publikace a užitečné odkazy
Obecné publikace
- Strathdee SA, Latka M, Campbell J, O'Driscoll PT, Golub ET, Kapadia F, Pollini RA, Garfein RS, Thomas DL, Hagan H; Study to Reduce Intravenous Exposures Project. Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis. 2005 Apr 15;40 Suppl 5(Suppl 5):S304-12. doi: 10.1086/427445.
- Campbell JV, Hagan H, Latka MH, Garfein RS, Golub ET, Coady MH, Thomas DL, Strathdee SA; STRIVE Project. High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. Drug Alcohol Depend. 2006 Feb 28;81(3):259-65. doi: 10.1016/j.drugalcdep.2005.07.005. Epub 2005 Aug 29.
- Golub ET, Latka M, Hagan H, Havens JR, Hudson SM, Kapadia F, Campbell JV, Garfein RS, Thomas DL, Strathdee SA; STRIVE Project. Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health. 2004 Jun;81(2):278-90. doi: 10.1093/jurban/jth114.
- Hagan H, Latka MH, Campbell JV, Golub ET, Garfein RS, Thomas DA, Kapadia F, Strathdee SA; Study to Reduce Intravenous Exposures Project Team. Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clin Infect Dis. 2006 Mar 1;42(5):669-72. doi: 10.1086/499951. Epub 2006 Jan 20. Erratum In: Clin Infect Dis. 2006 Jun 15;42(12):1818.
- Drumright LN, Hagan H, Thomas DL, Latka MH, Golub ET, Garfein RS, Clapp JD, Campbell JV, Bonner S, Kapadia F, Thiel TK, Strathdee SA. Predictors and effects of alcohol use on liver function among young HCV-infected injection drug users in a behavioral intervention. J Hepatol. 2011 Jul;55(1):45-52. doi: 10.1016/j.jhep.2010.10.028. Epub 2010 Nov 24.
- Kapadia F, Latka MH, Hagan H, Golub ET, Campbell JV, Coady MH, Garfein RS, Thomas DL, Bonner S, Thiel T, Strathdee SA. Design and feasibility of a randomized behavioral intervention to reduce distributive injection risk and improve health-care access among hepatitis C virus positive injection drug users: the Study to Reduce Intravenous Exposures (STRIVE). J Urban Health. 2007 Jan;84(1):99-115. doi: 10.1007/s11524-006-9133-7.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- DESPR DA014499
- 1R01DA014499 (Grant/smlouva NIH USA)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na HIV infekce
-
Ottawa Hospital Research InstitutePfizerDokončenoHIV infekce | HIV-1 infekce | Mycobacterium Avium Complex (MAC)Kanada
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...AbbottDokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-IntracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
PfizerDokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
PfizerDokončenoHIV infekce | Infekce Mycobacterium Avium-IntracellulareSpojené státy
-
PfizerDokončenoHIV infekce | Infekce Mycobacterium Avium-Intracellulare | Tuberkulóza, infekce MycobacteriumSpojené státy